| Todd D Freudenberger, MD | |
|
1135 116th Ave Ne, Suite 600, Bellevue, WA 98004-4623 | |
| (425) 454-2671 | |
| (425) 990-5260 |
| Full Name | Todd D Freudenberger |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 30 Years |
| Location | 1135 116th Ave Ne, Bellevue, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1932122876 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | MD00036246 (Washington) | Primary |
| 207RC0200X | Internal Medicine - Critical Care Medicine | MD00036246 (Washington) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Overlake Hospital Medical Center | Bellevue, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Overlake Medical Clinics Llc | 7012808827 | 350 |
News Archive
The current standard of care for early-stage breast cancer is breast conserving surgery (lumpectomy) to remove the tumor followed by radiation and hormone therapy to kill any remaining cells.
Nearly 11,500 people are diagnosed with a brain tumor every year in the UK with fewer than 15% surviving beyond 10 years. This week's announcement from the from the Department of Health and Social Care – following the death of Dame Tessa Jowell - that they would be doubling investment for brain cancer research to £40 million is a welcome commitment to helping achieve a goal our industry shares: finding innovative new treatments and cures for these diseases.
A clinical trial testing a candidate HIV vaccine known as the STEP study was halted in September 2007 after interim analysis indicated that the vaccine did not work. Moreover, subsequent analyses indicated that the vaccine made some individuals more susceptible to HIV, in particular individuals who had pre-existing immune effectors (antibodies) that recognized a component of the vaccine (adenovirus serotype 5 [Ad5]).
Results from the landmark RE-COVER(TM) study were presented today at the American Society of Hematology Annual Meeting and published online in the New England Journal of Medicine.
The quest to understand a prolonged infection in an infant being treated for leukemia has led to the St. Jude Children's Research Hospital discovery of a mutation that allows bacteria to tolerate normally effective antibiotic therapy. The report appears today in the scientific journal mBio.
› Verified 6 days ago
| Entity Name | Overlake Medical Clinics Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801828421 PECOS PAC ID: 7012808827 Enrollment ID: O20040322001533 |
News Archive
The current standard of care for early-stage breast cancer is breast conserving surgery (lumpectomy) to remove the tumor followed by radiation and hormone therapy to kill any remaining cells.
Nearly 11,500 people are diagnosed with a brain tumor every year in the UK with fewer than 15% surviving beyond 10 years. This week's announcement from the from the Department of Health and Social Care – following the death of Dame Tessa Jowell - that they would be doubling investment for brain cancer research to £40 million is a welcome commitment to helping achieve a goal our industry shares: finding innovative new treatments and cures for these diseases.
A clinical trial testing a candidate HIV vaccine known as the STEP study was halted in September 2007 after interim analysis indicated that the vaccine did not work. Moreover, subsequent analyses indicated that the vaccine made some individuals more susceptible to HIV, in particular individuals who had pre-existing immune effectors (antibodies) that recognized a component of the vaccine (adenovirus serotype 5 [Ad5]).
Results from the landmark RE-COVER(TM) study were presented today at the American Society of Hematology Annual Meeting and published online in the New England Journal of Medicine.
The quest to understand a prolonged infection in an infant being treated for leukemia has led to the St. Jude Children's Research Hospital discovery of a mutation that allows bacteria to tolerate normally effective antibiotic therapy. The report appears today in the scientific journal mBio.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Todd D Freudenberger, MD 1135 116th Ave Ne Ste 600, Bellevue, WA 98004-4623 Ph: (425) 454-2671 | Todd D Freudenberger, MD 1135 116th Ave Ne, Suite 600, Bellevue, WA 98004-4623 Ph: (425) 454-2671 |
News Archive
The current standard of care for early-stage breast cancer is breast conserving surgery (lumpectomy) to remove the tumor followed by radiation and hormone therapy to kill any remaining cells.
Nearly 11,500 people are diagnosed with a brain tumor every year in the UK with fewer than 15% surviving beyond 10 years. This week's announcement from the from the Department of Health and Social Care – following the death of Dame Tessa Jowell - that they would be doubling investment for brain cancer research to £40 million is a welcome commitment to helping achieve a goal our industry shares: finding innovative new treatments and cures for these diseases.
A clinical trial testing a candidate HIV vaccine known as the STEP study was halted in September 2007 after interim analysis indicated that the vaccine did not work. Moreover, subsequent analyses indicated that the vaccine made some individuals more susceptible to HIV, in particular individuals who had pre-existing immune effectors (antibodies) that recognized a component of the vaccine (adenovirus serotype 5 [Ad5]).
Results from the landmark RE-COVER(TM) study were presented today at the American Society of Hematology Annual Meeting and published online in the New England Journal of Medicine.
The quest to understand a prolonged infection in an infant being treated for leukemia has led to the St. Jude Children's Research Hospital discovery of a mutation that allows bacteria to tolerate normally effective antibiotic therapy. The report appears today in the scientific journal mBio.
› Verified 6 days ago
Joseph W Doucette, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1135 116th Ave Ne, Suite 600, Bellevue, WA 98004 Phone: 425-454-2656 Fax: 425-990-5261 | |
Roanne R E Selinger, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1135 116th Ave Ne, #560, Bellevue, WA 98004 Phone: 425-454-4768 Fax: 425-462-8021 | |
Patsy C Lazarous, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 11511 Ne 10th St, Bellevue, WA 98004 Phone: 425-502-3000 Fax: 844-620-1839 | |
Dr. Patricia Martin, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 1407 116th Ave Ne, Suite 200, Bellevue, WA 98004 Phone: 425-454-5046 Fax: 425-990-5261 | |
Dr. Rahil Barketali Roopani, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 1800 116th Ave Ne Ste 102, Bellevue, WA 98004 Phone: 425-947-9485 Fax: 425-977-9034 | |
David C Morton, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1135 116th Ave Ne, Suite 110a, Bellevue, WA 98004 Phone: 425-289-3100 Fax: 425-289-3103 | |
Shie-pon Tzung, MD PHD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1135 116th Ave Ne, #560, Bellevue, WA 98004 Phone: 425-454-4768 Fax: 425-462-8021 |